



(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/713 (2006.01)

(21) International Application Number:

PCT/US2021/045784

(22) International Filing Date:

12 August 2021 (12.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/065,190	13 August 2020 (13.08.2020)	US
63/214,016	23 June 2021 (23.06.2021)	US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **MURRAY, Justin K.**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **ZHANG, Jun**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **HOMANN, Oliver**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, Calif-

nia 91320-1799 (US). **LONG, Jason C.**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **MEADE, Bryan**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **PURCELL, Angela L.**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION




FIG. 4A




FIG. 4B

(57) Abstract: The present invention relates to RNAi constructs for reducing expression of the *MARC1* gene. Methods of using such RNAi constructs to treat or prevent liver fibrosis and fatty liver diseases, such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, are also described.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*